Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Completed NCT06545877

REKOVELLE PEN for S.C. Injection General Drug Use Survey (Controlled Ovarian Stimulation in Assisted Reproductive Technologies)

Conditions: Infertility

Sex: Female

Healthy volunteers: No

Enrollment: 571

Sponsor: Ferring Pharmaceuticals

Location: Ferring Investigational Site Omitama Ibaraki

Summary

This survey targets controlled ovarian stimulation with this drug for the development of multiple oocytes in women undergoing assisted reproduction (ART) such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

Eligibility Criteria

Inclusion Criteria: * Participants who received the REKOVELLE in controlled ovarian stimulation in assisted reproductive technologies and have consented to participate in the survey. Exclusion Criteria: * No exclusion criteria because data are collected under conditions of use in daily practice.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06545877). StuddyBuddy aggregates publicly available trial information.